Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation

Affiliations

• ¹ Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, Las Vegas, NV, USA.
• ² Compass Pathways, London, UK.
• ³ Eli Lilly and Company, Indianapolis, IN, USA.
• ⁴ Eisai Inc, Nutley, NJ, USA.
• ⁵ Samaritan Health Initiatives, Houston, TX, USA.
• ⁶ Pentara Corporation, Millcreek, UT, USA.
• ⁷ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Berry Consultants, LLC, Austin TX, USA.
• ⁸ CHDI Management, Inc. the company that manages the scientific activities of CHDI Foundation Princeton, NJ, USA, Faculdade Medicina University of Lisbon, Lisboa, Portugal.
• ⁹ Genentech Inc., South San Francisco, CA, USA.
• ¹⁰ Biogen, Cambridge, MA, USA at the time of advisory board.
• ¹¹ Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, Stockholm, Sweden, Ageing Epidemiology Research Unit (AGE), School of Public Health, Faculty of Medicine, Imperial College London, UK, Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
• ¹² Global R&D Partners, LLC., San Diego, CA, USA and University of California, San Diego, San Diego, CA, USA.
• ¹³ Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
• ¹⁴ SDG, LLC, Cambridge, MA, USA.
• ¹⁵ Independent Researcher, Albuquerque, NM, USA.
• ¹⁶ Alzheimer's Drug Discovery Foundation, New York, NY, USA.
• ¹⁷ Alzheimer's Drug Discovery Foundation, New York, NY, USA. Electronic address: [email protected].